2025 Q2 -tulosraportti
228 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 361 | - | - | ||
| 2 151 | - | - | ||
| 5 000 | - | - | ||
| 3 061 | - | - | ||
| 2 939 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 min sitten11,08•10=118kr hallo😀👏✌️- ·18 min sittenExclusive interview with Erik Digman Wiklund Ten-folded in two months – now Circio hunts for the next 10x The stock market rocket Circio has exploded from 1 krone to a double-digit price in record time. But according to CEO Erik Digman Wiklund, that's just the beginning. With a fully funded war chest, a global unique position in a medical paradigm shift, and a platform that can deliver continuous breakthroughs, he believes the company can ten-fold itself one more time.
·18 min sittenToday at 16.30, the media, journalists, and other registered parties gained access to the abstract. Now they have time to prepare articles and other things leading up to April 27th when the abstract will be published to the rest of us. This means that right now there are a lot of people who know something and have data that the rest of us don't know about. Will it have an influence on the share price? Probably not. But one can hope that some big sharks will trade on insider knowledge, just like in the days leading up to Circio announcing their partnership with United Immunity. Just a little speculation ;)
·21 min sitten- ·25 min sittenOslo, April 8, 2026: Circio Holding ASA ("the Company") hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well as certain post-period events year-to-date in 2026. Key highlights and events include: Up to 40-fold improved AAV expression in cardiac tissue in vivo (circVec generation 3.2), with circVec generation 4 achieving a further 50% increase compared to generation 3.2 New post-period in vivo data shows up to 50-fold improved circVec-AAV gene expression in the eye Fully funded feasibility study on circVec AAV gene therapy entered into with one of the top 5 global pharmaceutical companies New research collaborations established with The University of Texas Medical Branch (infectious diseases) and United Immunity Co. (in vivo CAR macrophage therapy) Rights issue completed in Q1 2026 with more than 50% oversubscription, raising gross proceeds of approximately NOK 68.6 million Net cash position as of March 31, 2026, of NOK 42 million Abstract selected for oral presentation at ASGCT's Annual Meeting in Boston, May 2026 More detailed information on key events and developments, as well as preliminary and unaudited financial information, including the Group's results for H2 2025 and net cash position as of December 31, 2025, and a going concern assessment, can be found in the attached presentation. The 2025 Annual Report will be published on April 15, 2026. For further information, please contact: Erik Digman Wiklund, Chief Executive Officer Phone: +47 413 33 536 E-mail: erik.wiklund@circio.com Lubor Gaal, Chief Financial Officer Phone: +34 683 34 3811 E-mail: lubor.gaal@circio.com About Circio Building circular RNA expression systems for improved gene and cell therapies Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy. Circio has established a unique circular RNA (circRNA) vector expression technology for next-generation RNA, DNA, and viral therapies. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic contexts, including genetic medicine, cell therapy, and chronic disease. It has shown 75-fold increased RNA half-life and up to 40-fold improved protein expression compared to conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold standard gene expression technology. circVec's R&D activities are carried out by its wholly-owned subsidiary Circio AB in Stockholm, Sweden. Attachment Key Events and Financial Highlights -- H2 2025 and Year-to-Date 2026 Circio Holding ASA – Key Events and Financial Highlights – H2 2025 and Year-to-Date 2026
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
228 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 min sitten11,08•10=118kr hallo😀👏✌️
- ·18 min sittenExclusive interview with Erik Digman Wiklund Ten-folded in two months – now Circio hunts for the next 10x The stock market rocket Circio has exploded from 1 krone to a double-digit price in record time. But according to CEO Erik Digman Wiklund, that's just the beginning. With a fully funded war chest, a global unique position in a medical paradigm shift, and a platform that can deliver continuous breakthroughs, he believes the company can ten-fold itself one more time.
- ·18 min sittenToday at 16.30, the media, journalists, and other registered parties gained access to the abstract. Now they have time to prepare articles and other things leading up to April 27th when the abstract will be published to the rest of us. This means that right now there are a lot of people who know something and have data that the rest of us don't know about. Will it have an influence on the share price? Probably not. But one can hope that some big sharks will trade on insider knowledge, just like in the days leading up to Circio announcing their partnership with United Immunity. Just a little speculation ;)
- ·21 min sitten
- ·25 min sittenOslo, April 8, 2026: Circio Holding ASA ("the Company") hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well as certain post-period events year-to-date in 2026. Key highlights and events include: Up to 40-fold improved AAV expression in cardiac tissue in vivo (circVec generation 3.2), with circVec generation 4 achieving a further 50% increase compared to generation 3.2 New post-period in vivo data shows up to 50-fold improved circVec-AAV gene expression in the eye Fully funded feasibility study on circVec AAV gene therapy entered into with one of the top 5 global pharmaceutical companies New research collaborations established with The University of Texas Medical Branch (infectious diseases) and United Immunity Co. (in vivo CAR macrophage therapy) Rights issue completed in Q1 2026 with more than 50% oversubscription, raising gross proceeds of approximately NOK 68.6 million Net cash position as of March 31, 2026, of NOK 42 million Abstract selected for oral presentation at ASGCT's Annual Meeting in Boston, May 2026 More detailed information on key events and developments, as well as preliminary and unaudited financial information, including the Group's results for H2 2025 and net cash position as of December 31, 2025, and a going concern assessment, can be found in the attached presentation. The 2025 Annual Report will be published on April 15, 2026. For further information, please contact: Erik Digman Wiklund, Chief Executive Officer Phone: +47 413 33 536 E-mail: erik.wiklund@circio.com Lubor Gaal, Chief Financial Officer Phone: +34 683 34 3811 E-mail: lubor.gaal@circio.com About Circio Building circular RNA expression systems for improved gene and cell therapies Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy. Circio has established a unique circular RNA (circRNA) vector expression technology for next-generation RNA, DNA, and viral therapies. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic contexts, including genetic medicine, cell therapy, and chronic disease. It has shown 75-fold increased RNA half-life and up to 40-fold improved protein expression compared to conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold standard gene expression technology. circVec's R&D activities are carried out by its wholly-owned subsidiary Circio AB in Stockholm, Sweden. Attachment Key Events and Financial Highlights -- H2 2025 and Year-to-Date 2026 Circio Holding ASA – Key Events and Financial Highlights – H2 2025 and Year-to-Date 2026
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 361 | - | - | ||
| 2 151 | - | - | ||
| 5 000 | - | - | ||
| 3 061 | - | - | ||
| 2 939 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
228 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 min sitten11,08•10=118kr hallo😀👏✌️
- ·18 min sittenExclusive interview with Erik Digman Wiklund Ten-folded in two months – now Circio hunts for the next 10x The stock market rocket Circio has exploded from 1 krone to a double-digit price in record time. But according to CEO Erik Digman Wiklund, that's just the beginning. With a fully funded war chest, a global unique position in a medical paradigm shift, and a platform that can deliver continuous breakthroughs, he believes the company can ten-fold itself one more time.
- ·18 min sittenToday at 16.30, the media, journalists, and other registered parties gained access to the abstract. Now they have time to prepare articles and other things leading up to April 27th when the abstract will be published to the rest of us. This means that right now there are a lot of people who know something and have data that the rest of us don't know about. Will it have an influence on the share price? Probably not. But one can hope that some big sharks will trade on insider knowledge, just like in the days leading up to Circio announcing their partnership with United Immunity. Just a little speculation ;)
- ·21 min sitten
- ·25 min sittenOslo, April 8, 2026: Circio Holding ASA ("the Company") hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well as certain post-period events year-to-date in 2026. Key highlights and events include: Up to 40-fold improved AAV expression in cardiac tissue in vivo (circVec generation 3.2), with circVec generation 4 achieving a further 50% increase compared to generation 3.2 New post-period in vivo data shows up to 50-fold improved circVec-AAV gene expression in the eye Fully funded feasibility study on circVec AAV gene therapy entered into with one of the top 5 global pharmaceutical companies New research collaborations established with The University of Texas Medical Branch (infectious diseases) and United Immunity Co. (in vivo CAR macrophage therapy) Rights issue completed in Q1 2026 with more than 50% oversubscription, raising gross proceeds of approximately NOK 68.6 million Net cash position as of March 31, 2026, of NOK 42 million Abstract selected for oral presentation at ASGCT's Annual Meeting in Boston, May 2026 More detailed information on key events and developments, as well as preliminary and unaudited financial information, including the Group's results for H2 2025 and net cash position as of December 31, 2025, and a going concern assessment, can be found in the attached presentation. The 2025 Annual Report will be published on April 15, 2026. For further information, please contact: Erik Digman Wiklund, Chief Executive Officer Phone: +47 413 33 536 E-mail: erik.wiklund@circio.com Lubor Gaal, Chief Financial Officer Phone: +34 683 34 3811 E-mail: lubor.gaal@circio.com About Circio Building circular RNA expression systems for improved gene and cell therapies Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy. Circio has established a unique circular RNA (circRNA) vector expression technology for next-generation RNA, DNA, and viral therapies. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic contexts, including genetic medicine, cell therapy, and chronic disease. It has shown 75-fold increased RNA half-life and up to 40-fold improved protein expression compared to conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold standard gene expression technology. circVec's R&D activities are carried out by its wholly-owned subsidiary Circio AB in Stockholm, Sweden. Attachment Key Events and Financial Highlights -- H2 2025 and Year-to-Date 2026 Circio Holding ASA – Key Events and Financial Highlights – H2 2025 and Year-to-Date 2026
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 361 | - | - | ||
| 2 151 | - | - | ||
| 5 000 | - | - | ||
| 3 061 | - | - | ||
| 2 939 | - | - |
Välittäjätilasto
Dataa ei löytynyt